In this video, viewers are taught what sputum is and the steps to collect a good sample for TB diagnostic purposes. The video can be shown prior to submitting sputum (e.g., spot samples, home visits, morning samples).
The webinar presents information on the potential clinical implications of TB and diabetes, the epidemiology of TB and diabetes, and diabetes and prevention of TB. The webinar also describes what a TB program can do about TB and diabetes.
This material summarizes the U.S. recommendations for latent TB infection testing and treatment. The document includes information on who should be tested for TB infection, recommended treatment regimens for latent TB infection, and more.
The 57-minute presentation by Charles L. Daley, MD, includes information on the epidemiology, diagnosis, and treatment of NTM pulmonary disease.
In this video, viewers are taught what sputum is and the steps to collect a good sample for TB diagnostic purposes. The video can be shown prior to submitting sputum (e.g., spot samples, home visits, morning samples).
This fact sheet highlights data on TB in children, information on the neglect of TB in children, and new tools available for TB testing and treatment.
This document informs national TB programs and stakeholders about the key implications for the treatment of drug-resistant tuberculosis. This resource is available before the release of the updated guidelines in order for planning at the country level. The guidelines are expected to be released in 2020.
The materials were developed for clinicians to use with patients while discussing the 12-dose regimen for the treatment of latent TB infection. The materials include a patient education brochure, medication tracker, and symptom checklist. The brochure contains information on latent TB infection, the 12-dose regimen, and adverse events. The medication tracker includes space to write treatment schedules, medication intake, and doctor/clinic contact information. There is also a checklist of signs and symptoms that may develop while using the 12-dose regimen.
This material was developed for clinicians to use with patients that are prescribed the three months of daily isoniazid plus rifampin (3HR) regimen for the treatment of latent TB infection. There is space to write treatment information, medication intake, and doctor/clinic contact information. There is also a checklist of signs and symptoms that may develop while using the 3HR regimen.
Speakers for this webinar include the Deputy Director of the Global TB Institute and a survivor of MDR-TB. By the end of the webinar, participants will be able to: define stigma in the context of tuberculosis prevention and care, describe how stigma affects persons with tuberculosis, and apply interventions in the health care setting and community to reduce stigma.
